SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-24-119183
Filing Date
2024-11-14
Accepted
2024-11-14 16:53:53
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5842
  Complete submission text file 0001104659-24-119183.txt   7536
Mailing Address 130 MAIN ST 2ND FLOOR NEW CANAAN CT 06840
Business Address 130 MAIN ST 2ND FLOOR NEW CANAAN CT 06840 203-909-6430
Nantahala Capital Partners Limited Partnership (Filed by) CIK: 0001502725 (see all company filings)

IRS No.: 201220305 | State of Incorp.: MA | Fiscal Year End: 1210
Type: SCHEDULE 13G/A

Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Subject) CIK: 0001766140 (see all company filings)

IRS No.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92874 | Film No.: 241463832
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)